Cellular Immunotherapy for Septic Shock

PHASE2UnknownINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

March 31, 2018

Primary Completion Date

February 29, 2020

Study Completion Date

October 31, 2020

Conditions
Septic ShockSepsisPathologic ProcessesShockInfectionSystemic Inflammatory Response SyndromeInflammation
Interventions
BIOLOGICAL

Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells

Cryopreserved Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.

OTHER

Placebo

Placebo, with excipients, will be administered intravenously.

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Ontario Institute for Regenerative Medicine (OIRM)

UNKNOWN

collaborator

Stem Cell Network

OTHER

lead

Ottawa Hospital Research Institute

OTHER